… This study described treatment patterns and clinical outcomes among patients with …
This study also found that 1L IO treatment, either as monotherapy or in combination with …

… either agent alone, with similar IC 50 with the combination regardless of the EGFR TKI
subtype [20]. However, clinical evidence for this combination is limited [34], [35]. Two ongoing …

… hybridization was negative for either gene rearrangement. … may be predictive for improved
outcomes for leptomeningeal … improved clinical outcomes when compared with EGFR exon 21 …

… The frequency of uncommon deletions of exon 19 was 36%. When delE746_A750 (n = 68)
was compared to the other deletions in exon 19 (n = 38), no differences were found, either in …

… In this multi-institutional retrospective case series analysis of 185 patients with KIT exon 9–mutated
GIST who received adjuvant imatinib either at 400 mg per day or 800 mg per day, …

Objective: To describe the baseline clinical and functional characteristics of an international
cohort of 193 patients with dysferlinopathy. Methods: The Clinical Outcome Study for …

… These factors can bind particular enhancer and silencer sequences either within the
exon itself (ESE and ESS) or in the nearby flanking regions (ISE and ISS) and help increase/…

… However, some patients will either present with advanced-stage disease or … in exon 10 of
ATR would be associated with more aggressive phenotypes and worse clinical outcomes. The …

… Virtually all of these mutations cause either exon skipping or cryptic splice-site utilization,
resulting in the severe reduction or absence of normally spliced mRNA. In addition, mutations …

… In an expansion cohort of patients with MET exon 14 alterations on the … exon 14-altered
lung cancers of any stage who were identified between 1 January 2014 and 1 May 2017 at either …